eligibility_summary
Include: ECOG 0–1, recurrent high‑grade endometrial (1–3 lines), platinum‑resistant high‑grade serous EOC (prior‑line caps, FRα‑naive unless Cohort C), cervical SCC/adenocarcinoma/adenosquamous (1–4 lines). Measurable disease (except dose‑escalation), provide tissue/biopsy, adequate organs. Exclude: disallowed histology, primary platinum‑refractory, >20% marrow RT, >G1 neuropathy, ocular disease, serious comorbidity (cardiac, infection, stroke, liver B/C, ILD), mAb allergy, pregnancy, prior FRα (except C), untreated CNS mets, other cancer <3y. CPI needed if available for cervical CPS>1 or endometrial.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: IMGN151, an anti–folate receptor alpha (FRα) antibody-drug conjugate (ADC) given IV every 3 weeks. Mechanism of action: The monoclonal antibody component selectively binds FRα on tumor cells, is internalized via FRα-mediated endocytosis, and releases an intracellular cytotoxic payload to induce tumor-cell death (with potential bystander effect), while enabling systemic PK typical of ADCs. Cells/pathways targeted: FRα-overexpressing epithelial tumor cells in recurrent gynecologic cancers (high-grade serous ovarian/fallopian tube/primary peritoneal, endometrial, and cervical). Key pathway: FRα cell-surface receptor engagement and internalization leading to payload-mediated cytotoxicity.